Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference - PubMed (original) (raw)
Review
. 2003 May;37(5):1202-19.
doi: 10.1053/jhep.2003.50193.
Affiliations
- PMID: 12717402
- DOI: 10.1053/jhep.2003.50193
Review
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference
Brent A Neuschwander-Tetri et al. Hepatology. 2003 May.
Erratum in
- Hepatology. 2003 Aug;38(2):536
Abstract
Fatty liver disease that develops in the absence of alcohol abuse is recognized increasingly as a major health burden. This report summarizes the presentations and discussions at a Single Topic Conference held September 20-22, 2002, and sponsored by the American Association for the Study of Liver Diseases. The conference focused on fatty liver disorders. Estimates based on imaging and autopsy studies suggest that about 20% to 30% of adults in the United States and other Western countries have excess fat accumulation in the liver. About 10% of these individuals, or fully 2% to 3% of adults, are estimated to meet current diagnostic criteria for nonalcoholic steatohepatitis (NASH). Sustained liver injury leads to progressive fibrosis and cirrhosis in a fraction, possibly up to one third, of those with NASH, and NASH may be a cause of cryptogenic cirrhosis. NASH is now a significant health issue for obese children as well, leading to cirrhosis in some. The diagnostic criteria for NASH continue to evolve and rely on the histologic findings of steatosis, hepatocellular injury (ballooning, Mallory bodies), and the pattern of fibrosis. Generally recognized indications for biopsy include establishing the diagnosis and staging of the injury, but strict guidelines do not exist. Liver enzymes are insensitive and cannot be used reliably to confirm the diagnosis or stage the extent of fibrosis. Older age, obesity, and diabetes are predictive of fibrosis. The pathogenesis of NASH is multifactorial. Insulin resistance may be an important factor in the accumulation of hepatocellular fat, whereas excess intracellular fatty acids, oxidant stress, adenosine triphosphate (ATP) depletion, and mitochondrial dysfunction may be important causes of hepatocellular injury in the steatotic liver. Efforts are underway to refine the role of insulin resistance in NASH and determine whether improving insulin sensitivity pharmacologically is an effective treatment. An altered lifestyle may be a more effective means of improving insulin sensitivity. The research agenda for the future includes establishing the role of insulin resistance and abnormal lipoprotein metabolism in NASH, determining the pathogenesis of cellular injury, defining predisposing genetic abnormalities, identifying better noninvasive predictors of disease, and defining effective therapy.
Similar articles
- Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis.
Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R. Medina J, et al. Diabetes Care. 2004 Aug;27(8):2057-66. doi: 10.2337/diacare.27.8.2057. Diabetes Care. 2004. PMID: 15277442 Review. - Evolving pathophysiologic concepts in nonalcoholic steatohepatitis.
Neuschwander-Tetri BA. Neuschwander-Tetri BA. Curr Gastroenterol Rep. 2002 Feb;4(1):31-6. doi: 10.1007/s11894-002-0035-x. Curr Gastroenterol Rep. 2002. PMID: 11825539 Review. - [Nonalcoholic steatohepatitis: pathogenesis and treatment].
Park SH. Park SH. Korean J Hepatol. 2008 Mar;14(1):12-27. doi: 10.3350/kjhep.2008.14.1.12. Korean J Hepatol. 2008. PMID: 18367854 Review. Korean. - Etiopathogenesis of nonalcoholic steatohepatitis.
Chitturi S, Farrell GC. Chitturi S, et al. Semin Liver Dis. 2001;21(1):27-41. doi: 10.1055/s-2001-12927. Semin Liver Dis. 2001. PMID: 11296694 Review. - From fatty liver to fibrosis: a tale of "second hit".
Basaranoglu M, Basaranoglu G, Sentürk H. Basaranoglu M, et al. World J Gastroenterol. 2013 Feb 28;19(8):1158-65. doi: 10.3748/wjg.v19.i8.1158. World J Gastroenterol. 2013. PMID: 23483818 Free PMC article. Review.
Cited by
- Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels.
Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Sata M, Kanemasa K, Kohgo Y, Saibara T, Chayama K, Itoh Y, Yoshikawa T, Anzai K, Fujimoto K, Okanoue T, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Yoneda M, et al. J Gastroenterol. 2013 Sep;48(9):1051-60. doi: 10.1007/s00535-012-0704-y. Epub 2012 Nov 27. J Gastroenterol. 2013. PMID: 23184095 - MTHFR 677C/T and 1298A/C mutations and non-alcoholic fatty liver disease.
Kasapoglu B, Turkay C, Yalcin KS, Kosar A, Bozkurt A. Kasapoglu B, et al. Clin Med (Lond). 2015 Jun;15(3):248-51. doi: 10.7861/clinmedicine.15-3-248. Clin Med (Lond). 2015. PMID: 26031974 Free PMC article. - Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis.
Kumar A, Sharma A, Duseja A, Das A, Dhiman RK, Chawla YK, Kohli KK, Bhansali A. Kumar A, et al. J Clin Exp Hepatol. 2013 Mar;3(1):12-8. doi: 10.1016/j.jceh.2012.10.009. Epub 2012 Nov 2. J Clin Exp Hepatol. 2013. PMID: 25755466 Free PMC article. - International trends in primary liver cancer incidence from 1973 to 2007.
Zhang Y, Ren JS, Shi JF, Li N, Wang YT, Qu C, Zhang Y, Dai M. Zhang Y, et al. BMC Cancer. 2015 Mar 4;15:94. doi: 10.1186/s12885-015-1113-4. BMC Cancer. 2015. PMID: 25879744 Free PMC article. - Diagnosis of non-alcoholic fatty liver disease (NAFLD).
Yki-Järvinen H. Yki-Järvinen H. Diabetologia. 2016 Jun;59(6):1104-11. doi: 10.1007/s00125-016-3944-1. Epub 2016 Apr 18. Diabetologia. 2016. PMID: 27091184 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources